glp-1 drug companies Analogues Market Size, Share & Growth Drivers By 2034 Asia-Pacific Glucagon-like Peptide-1 (GLP-1) Agonists

Almost 60 percent of adults have said they have heard at least some about these drugs, according to a 2024 KFF Health Tracking Poll

Published June 24, 2023

All GLP-1RAs [reviewed in (81)] and, more recently, the dual incretin receptor agonist tirzepatide, have been shown to lower postprandial triglyceride and ApoB-48 levels significantly (82)

161 However, these problems have not been shown to have a clear causal relationship with GLP-1RA in the general population, and there is a lack of data specific to the MASLD population, especially in individuals without co-existing T2DM

Mounjaro (tirzepatide) Approved - A dual-action injectable targeting GLP-1 and GIP receptors